MiNK Therapeutics, Inc. (INKT)
NCM – Real vaqt narxi. Valyuta: USD
11.64
+0.33 (2.92%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
12.10
+0.46 (3.95%)
Bozordan keyin: Jun 26, 2026, 6:03 PM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
11.64
+0.33 (2.92%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
12.10
+0.46 (3.95%)
Bozordan keyin: Jun 26, 2026, 6:03 PM EDT
MiNK Therapeutics, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, rak va boshqa immunitet vositachiligidagi kasalliklarni davolash uchun allogenik, tayyor, inkubatsiyalanmagan tabiiy killer T (iNKT) hujayra terapiyalarini kashf qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirish bilan shug'ullanadi. Kompaniya agenT-797ni ishlab chiqmoqda, bu tayyor, allogenik, tabiiy iNKT hujayra terapiyasi bo'lib, u agenT-797, botensilimab va balstilimabning ramucirumab va paclitaxel bilan kombinatsiyasining klinik xavfsizligi va samaradorligi uchun 2-bosqichli klinik sinovda; ilgari davolangan, ilg'or oshqozon, oshqozon yoki oshqozon-teshik adenokarsinomasi bo'lgan bemorlar uchun; refrakter qattiq o'smalar uchun PD-1 blokirovka inhibitorlari, pembrolizumab va nivolumab bilan kombinatsiyalangan monoterapiya sifatida 1-bosqichli sinovda; va o'rtacha va og'ir virusli o'tkir respirator distress sindromi (ARDS) ni davolash uchun 1-bosqichli sinovda. Shuningdek, u qattiq o'smalar va yallig'lanishni davolash uchun FAP-CAR-iNKT dasturiga yo'naltirilgan IL-15 zirhli o'simta stromalari bo'lgan MiNK-215ni; va avtoimmunitet kasalliklari, shu jumladan graft-versus-host kasalligining oldini olish uchun B hujayra etuklik antigeniga yo'naltirilgan IL-15 zirhli CAR-iNKT dasturi bo'lgan MiNK-413ni ishlab chiqmoqda. Kompaniya metastatik o'smalarni aniqlash va davolash uchun Autonomous Therapeutics; qattiq o'smalardagi maqsadlarga qarshi T-hujayra retseptorlari terapiyalarini kashf qilish va ishlab chiqish uchun ImmunoScape, Inc.; va bolalar saratonini davolash uchun PRAME-yo'naltirilgan iNKT hujayra terapiyasini ishlab chiqish uchun C-Further bilan hamkorlik qiladi. Kompaniya ilgari AgenTus Therapeutics, Inc. nomi bilan tanilgan va 2021 yil iyun oyida MiNK Therapeutics, Inc. nomini olgan. Kompaniya 2017 yilda tashkil etilgan va Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Garo H. Armen Ph.D. | Executive Chairman |
| Dr. Jennifer S. Buell Ph.D. | Co-Founder, President, CEO & Director |
| Mr. Austin Charette | Principal Accounting Officer |
| Ms. Melissa Orilall | Principal Financial Officer |
| Ms. Terese C. Hammond M.D. | Head of Inflammatory & Pulmonary Diseases |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-23 | 8-K | inkt-20260617.htm |
| 2026-05-15 | 8-K | inkt-20260515.htm |
| 2026-05-15 | 10-Q | inkt-20260331.htm |
| 2026-03-31 | 8-K | inkt-20260331.htm |
| 2026-03-31 | 10-K | inkt-20251231.htm |
| 2026-03-27 | 8-K | inkt-20260327.htm |
| 2026-03-19 | 8-K | inkt-20260313.htm |
| 2026-01-02 | 8-K | inkt-20251229.htm |
| 2025-12-10 | S-3/A | d62147ds3a.htm |
| 2025-12-10 | CORRESP | filename1.htm |